Treats severe asthma and with an eosinophilic phenotype. Sold as Nucala. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Mepolizumab (sold as Nucala), first approved Nov 4, 2015, with 7 new uses approved and 0 published complete response letters.
| T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPDAsthma, COPD (Chronic Obstructive Pulmonary Disease) · Shanghai Pulmonary Hospital, Shanghai, China | — | Recruiting | Sep 16, 2026 |
| Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).Chronic Rhinosinusitis With Nasal Polyps · Instituto de Investigación Marqués de Valdecilla | Phase 4 | Recruiting | Sep 11, 2026 |
| Benralizumab Effectiveness in EGPAEosinophilic Granulomatosis With Polyangiitis (EGPA) · European EGPA Study Group | — | Recruiting | Sep 11, 2026 |
| Expression of TSLP Isoforms in AsthmaAsthma Atopic, Asthma Severe Persistent Uncontrolled · Medical University of Warsaw | — | Recruiting | Aug 26, 2026 |
| Airway Dysfunction, Occlusions and Remodeling: COPD Patients and MepolizumabCOPD (Chronic Obstructive Pulmonary Disease) · Western University, Canada | Phase 4 | Not yet recruiting | Aug 6, 2026 |
| Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With BiologicsSevere Eosinophilic ACOS (Asthma-COPD Overlap) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — | Not yet recruiting | May 22, 2026 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPAEGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma · Azienda Ospedaliero Universitaria di Cagliari | Phase 4 | Enrolling by invitation | Jan 15, 2026 |
| Complete Remission After Treatment With Biologics for Nasal PolypsNasal Polyps · Copenhagen University Hospital, Rigshospitalet | Phase 4 | Recruiting | Dec 5, 2025 |
| Nov 4, 2015 | NucalaBLA 125526 · New molecular entity | Glaxosmithkline LLC | 9 | Marketed |
| Jun 6, 2019 | NucalaBLA 761122 · New dosage form | Glaxosmithkline | 7 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Glaxosmithkline LLC